Full-Time
Confirmed live in the last 24 hours
Develops brain-computer interfaces for medical use
$143k - $235kAnnually
Mid
Fremont, CA, USA
You match the following Neuralink's candidate preferences
Employers are more likely to interview you if you match these preferences:
Neuralink develops brain-computer interfaces (BCIs) that enable direct communication between the brain and external devices. Its main product, the N1 Implant, is a small, fully implantable device that allows users to control computers or mobile devices. The implant works by processing neural signals with custom low-power chips and transmitting the data wirelessly to a dedicated application, which translates brain activity into computer commands. What sets Neuralink apart from competitors is its focus on both medical applications for individuals with mobility issues and the potential for cognitive enhancement for a broader audience. The company's goal is to restore autonomy to those with unmet medical needs while exploring the possibilities of human-computer interaction.
Company Size
201-500
Company Stage
Series D
Total Funding
$667.3M
Headquarters
Fremont, California
Founded
2016
Help us improve and share your feedback! Did you find this helpful?
An opportunity to change the world and work with some of the smartest and the most talented experts from different fields.
Growth potential. We rapidly advance team members who have an outsized impact.
Excellent medical, dental, and vision insurance through a PPO plan; parental leave.
Flexible time off + paid holidays.
Equity + 401(k) plan.
Commuter Benefits.
Meals provided.
A brain-computer interface (BCI) startup called Paradromics, a competitor to Elon Musk's Neuralink that's aiming to control computers using brain implants, is partnering with Saudi Arabia's megalomaniac Neom city-building project.
By Nancy DahlbergElon Musk may have Washington on his mind, but his brain chips are headed to Miami.Neuralink, Musk’s startup, has selected the University of Miami’s Miller School of Medicine to be the second US clinical trial site to test whether its brain chip – a brain-computer interface implant – can give people who are paralyzed the ability to use only their thoughts to control their smartphones, computers and other electronic devices.“The Miami Project to Cure Paralysis and the University of Miami are renowned for their pioneering research in neural interfaces for the treatment of debilitating neurological conditions such as spinal cord injury and ALS. We look forward to partnering with them as a site for our PRIME Study,” DJ Seo, co-founder, president and COO at Neuralink, said in a statement.The Neuralink PRIME (Precise Robotically Implanted Brain-Computer Interface) Study will seek to assess the safety and functionality of Neuralink’s N1 Implant. This brain-computer interface (BCI) implant establishes a wireless, digital link between the brain and computers. The study will also evaluate Neuralink’s R1 Robot, a surgical robot that precisely and rapidly places the N1 Implant’s ultra-fine electrode threads within microns of targeted neurons.“This study will use the latest technological advances in BCI approaches for improving function and quality of life in individuals living with the consequences of chronic spinal cord injury, as well as amyotrophic lateral sclerosis (ALS),” said Dr. Allan Levi, a UM professor and chair of neurological surgery and a co-investigator, in the announcement.The implant procedure will be carried out by Neuralink scientists and a multidisciplinary team of neurosurgeons, neuroscientists and biomedical engineers at The Miami Project to Cure Paralysis and the Miller School of Medicine.The procedure is less invasive than other types of brain surgeries because the Neuralink procedure occurs on the superficial surface area of the brain and requires a relatively small incision, he told the Miami Herald. “I really think it’s going to be a game changer.” Neuralink was founded in 2016
Founded by ex-Neuralink co-founder Ben Rapoport, it competes with Elon Musk's Neuralink, which has raised over $685 million.
In 2023, the Physicians Committee for Responsible Medicine and four US lawmakers urged the SEC to investigate Neuralink for possible securities fraud, alleging that the company made misleading claims about its technology.
The regulatory approval comes as Neuralink is expanding its presence in Texas, where the company is building a $14.7 million facility in Del Valle.